HTBA Acquired by Miura Partners in Strategic Growth Move
Deal News | Nov 05, 2024 | Miura Partners
Miura Partners, a private equity firm with expertise in mid-market buy-outs, has announced the acquisition of HealthTech Bioactives (HTBA). HTBA, a leading producer of natural ingredients such as citrus flavonoids and vitamin B12, operates in diverse sectors including pharmaceuticals, nutraceuticals, and food. Based in Barcelona with operations in Murcia and Cincinnati, HTBA has a client base spanning over 60 countries. The acquisition, part of Miura Fund IV's strategy, aims to strengthen HTBA's role as a key player in the natural ingredients market by funding both organic growth and acquisitions. Miura Partners was supported by advisors such as Houlihan Lokey for M&A, Linklaters for legal matters, KPMG for due diligence, and Bain & Company for commercial due diligence. The completion of the deal awaits approval from Spanish regulators. Miura's investment ethos focuses on sustainable growth and innovation, which aligns with HTBA's mission to deliver high-quality, sustainable health solutions globally. This acquisition reflects Miura’s strategy to invest in scalable businesses with significant growth potential.
Sectors
- Private Equity
- Health & Nutrition
- Food & Beverage
- Manufacturing
Geography
- Spain – HTBA is headquartered in Barcelona and has its main manufacturing facility in Murcia, Spain.
- United States – HTBA operates a significant operations center in Cincinnati, Ohio, indicating its geographical presence in the US.
Industry
- Private Equity – Miura Partners, a private equity firm, is involved in the acquisition of HTBA, making this relevant to the private equity sector.
- Health & Nutrition – HTBA is a producer of natural ingredients used in health-related sectors such as pharmaceuticals and nutraceuticals, fitting into the health and nutrition industry.
- Food & Beverage – HTBA's products, including natural ingredients and vitamin B12, are used in the food and beverage industry.
- Manufacturing – HTBA's production of flavonoids and vitamins positions it within the manufacturing sector, focusing on high-value-added ingredients.
Financials
- 475 million – The size of Miura Fund IV, which financed the acquisition of HTBA.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Miura Partners | Bidding Company | Company | A private equity firm with offices in Barcelona and Madrid, specializing in mid-market buy-outs. |
| HealthTech Bioactives (HTBA) | Target Company | Company | A global leader in the manufacturing and commercialization of natural ingredients, including flavonoids and vitamin B12. |
| Houlihan Lokey | M&A Advisor | Company | Provided M&A advisory to Miura Partners for the acquisition. |
| Linklaters | Legal Advisor | Company | Provided legal advisory services to Miura Partners in the transaction. |
| KPMG | Due Diligence Advisor | Company | Conducted due diligence for Miura Partners during the acquisition process. |
| Bain & Company | Commercial Due Diligence Advisor | Company | Provided commercial due diligence services to Miura Partners for the acquisition. |
| Spanish Regulator | Regulatory Approval | Government | Pending approval of the transaction between Miura Partners and HTBA. |